3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Stomach Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma, Endometrioid
1
Breast Neoplasms
1
Advanced Colorectal Cancer
1
Interventions
Fluorouracil
98
Oxaliplatin
94
Leucovorin
86
Irinotecan
70
Gemcitabine
66
Bevacizumab
62
Capecitabine
60
Cetuximab
42
pembrolizumab
37
Cisplatin
30
Nivolumab
25
Drug Therapy
25
130-nm albumin-bound paclitaxel
22
Specimen Handling
20
Folfox protocol
20
Panitumumab
19
Paclitaxel
19
Magnetic Resonance Spectroscopy
18
Albumin-Bound Paclitaxel
17
Biopsy
16
IFL protocol
15
Floxuridine
15
Docetaxel
15
Cyclophosphamide
15
Sorafenib
14
regorafenib
12
Erlotinib Hydrochloride
12
aflibercept
11
Radiofrequency Ablation
11
fludarabine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
defactinib
×
Gastrointestinal
×
Clear all
NCT05669482
2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2
Active not recruiting
40 enrolled